GLP1R and Hepatic steatosis: In addition to attenuating hepatic steatosis, combined GIPR/GLP1R agonism strongly lowered hepatic inflammation as evidenced by a decreased number of moKCs possibly as a result of lowered expression of hepatic chemokines involved in leukocyte trafficking to the liver.